COX-2 chronology

Hawkey, C. J.
November 2005
Gut;Nov2005, Vol. 54 Issue 11, p1509
Academic Journal
The role of selective cyclooxygenase (COX)-2 inhibitors in medical practice has become controversial since evidence emerged that their use is associated with an increased risk of myocardial infarction. Selective COX-2 inhibitors were seen as successor to non-selective non-steroidal anti-inflammatory drugs, in turn successors to aspirin. The importance of pain relief means that such drugs have always attracted attention. The fact that they work through inhibition of cyclooxygenase, are widespread, and have multiple effects also means that adverse effects that were unanticipated (even though predictable) have always emerged. In this paper I therefore present an historical perspective so that the lessons of the past may be applied to the present.


Related Articles

  • A Randomized Trial of Low-Dose Aspirin in the Primary Prevention of Cardiovascular Disease in Women. Ridker, Paul M; Cook, Nancy R.; Lee, I-Min; Gordon, David; Gaziano, J. Michael; Manson, JoAnn E.; Hennekens, Charles H.; Buring, Julie E. // New England Journal of Medicine;3/31/2005, Vol. 352 Issue 13, p1293 

    Background: Randomized trials have shown that low-dose aspirin decreases the risk of a first myocardial infarction in men, with little effect on the risk of ischemic stroke. There are few similar data in women. Methods: We randomly assigned 39,876 initially healthy women 45 years of age or older...

  • Cox-2 risk 'overblown'. Cressey, Daniel // Pulse;5/4/2006, Vol. 66 Issue 18, p8 

    The article reports on research headed by King's College London senior instructor Ernest Choy probing the contribution of non-steroidal anti-inflammatory drugs and cox-2 inhibitors to incidence of heart attack in Great Britain. The study shows that the medicine carries minimal risk coronary...

  • NSAIDs after a MI could be fatal.  // Reactions Weekly;12/3/2005, Issue 1080, p5 

    The article discusses research being done on the association of COX-2 inhibitors and other nonsteroidal anti-inflammatory agents (NSAID) with the risk of death after a myocardial infarction (MI). It references a study by G. H. Gislason et al published in the October 25, 2005 issue of the...

  • Treatment of Unstable Angina Pectoris/Non-ST-Segment Elevation Myocardial Infarction in Elderly Patients. Aronow, Wilbert S. // Journals of Gerontology Series A: Biological Sciences & Medical ;Oct2003, Vol. 58 Issue 10, p927 

    Elderly patients with unstable angina pectoris/non-ST-segment elevation myocardial infarction should be hospitalized. Precipitating factors should be identified and corrected. Electrocardiogram monitoring is important. Aspirin should be given as soon as possible and continued indefinitely....

  • Asasantin Retard.  // Royal Society of Medicine: Medicines;2002, p88 

    The article presents information on Asasantin Retard, a proprietary, prescription-only compound preparation of the antiplatelet drugs dipyridamole and aspirin. It can be used to prevent thrombosis in the treatment of ischaemic stroke and ischaemic attacks. It is available in the form of capsules.

  • Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis. Hippisley-Cox, Julia; Coupland, Carol // BMJ: British Medical Journal (International Edition);6/11/2005, Vol. 330 Issue 7504, p1366 

    Presents a study to determine the comparative risk of myocardial infarction in patients treated with cyclo-oxygenase-2 and other non-steroidal anti-inflammatory drugs (NSAIDs) in primary care during 2000 and 2004, the risks in patients with and without coronary heart disease, as well as the risk...

  • Changing roles of anticoagulant and antiplatelet treatment during percutaneous coronary intervention. Kelly, R. V.; Sleinhubi, S. // Heart;Jun2005 Supplement 3, Vol. 91, piii16 

    The article focuses on the changing roles of anticoagulant and antiplatelet treatment during percutaneous coronary intervention (PCI). Antiplatelet and anticoagulant treatments are essential in the management of PCI patients. Aspirin should be given to all patients and likely maintained...

  • A multi-country economic evaluation of low-dose aspirin in the primary prevention of cardiovascular disease. Lamotte, Mark; Annemans, Lieven; Evers, Thomas; Kubin, Maria // PharmacoEconomics;2006, Vol. 24 Issue 2, p155 

    Background: Low-dose aspirin (acetylsalicylic acid) is standard care in patients with a history of cardiovascular disease (CVD). The use of low-dose aspirin in primary prevention is not yet fully established, although meta-analyses and US and European guidelines support its use in...

  • The Value of Clopidogrel in Addition to Standard Therapy in Reducing Atherothrombotic Events. Weintraub, William; J√ľnsson, Bengt; Bertrand, Michel // PharmacoEconomics;2004 Supplement 4, Vol. 22, p29 

    The recent multinational, randomised, prospective studies Clopidogrel in Unstable Angina to Prevent Recurrent Events (CURE), Percutaneous Coronary Intervention substudy of CURE (PCI--CURE) and Clopidogrel for the Reduction of Events During Observation (CREDO) have demonstrated the clinical...


Read the Article


Sign out of this library

Other Topics